Literature DB >> 19357694

HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain.

J R Goss1, M S Gold, J C Glorioso.   

Abstract

Chronic pain is a serious medical condition with millions of sufferers for whom long-term therapies are either lacking or inadequate. Here we review the use of herpes simplex virus vectors as therapeutic tools to treat chronic pain by gene therapy. We describe an approach to inhibit chronic pain signaling whereby vector-mediated genes transferred to sensory nerves will modify the primary afferent nociceptor to prevent pain signaling to second-order nerves in the spinal cord. This approach may be used to reverse the chronic pain state of the nociceptor and could affect downstream pain-related changes in the central nervous system.

Entities:  

Mesh:

Year:  2009        PMID: 19357694      PMCID: PMC3426358          DOI: 10.1038/gt.2009.24

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  49 in total

Review 1.  Engineering herpes simplex virus vectors for CNS applications.

Authors:  D Wolfe; W F Goins; M Yamada; S Moriuchi; D M Krisky; T J Oligino; P C Marconi; D J Fink; J C Glorioso
Journal:  Exp Neurol       Date:  1999-09       Impact factor: 5.330

2.  Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion.

Authors:  J R Goss; M Mata; W F Goins; H H Wu; J C Glorioso; D J Fink
Journal:  Gene Ther       Date:  2001-04       Impact factor: 5.250

3.  Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy.

Authors:  Munmun Chattopadhyay; James Goss; Darren Wolfe; William C Goins; Shaohua Huang; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Brain       Date:  2004-01-28       Impact factor: 13.501

Review 4.  Delivery using herpes simplex virus: an overview.

Authors:  William F Goins; Darren Wolfe; David M Krisky; Qing Bai; Ed A Burton; David J Fink; Joseph C Glorioso
Journal:  Methods Mol Biol       Date:  2004

5.  A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.

Authors:  Prisca Honore; Carol T Wismer; Joe Mikusa; Chang Z Zhu; Chengmin Zhong; Donna M Gauvin; Arthur Gomtsyan; Rachid El Kouhen; Chih-Hung Lee; Kennan Marsh; James P Sullivan; Connie R Faltynek; Michael F Jarvis
Journal:  J Pharmacol Exp Ther       Date:  2005-04-18       Impact factor: 4.030

6.  Gene transfer of glutamic acid decarboxylase reduces neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; David J Fink
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

7.  Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.

Authors:  Guoying Zhou; Bernard Roizman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons.

Authors:  J Braz; C Beaufour; A Coutaux; A L Epstein; F Cesselin; M Hamon; M Pohl
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

9.  Engineering an endomorphin-2 gene for use in neuropathic pain therapy.

Authors:  Darren Wolfe; Shuanglin Hao; Jian Hu; Rahul Srinivasan; James Goss; Marina Mata; David J Fink; Joseph C Glorioso
Journal:  Pain       Date:  2007-03-28       Impact factor: 6.961

10.  The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender.

Authors:  James M Hill; Melvyn J Ball; Donna M Neumann; Ann M Azcuy; Partha S Bhattacharjee; Saadallah Bouhanik; Christian Clement; Walter J Lukiw; Timothy P Foster; Manish Kumar; Herbert E Kaufman; Hilary W Thompson
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

View more
  11 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

2.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

Review 3.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 4.  A bright future? Optogenetics in the periphery for pain research and therapy.

Authors:  Aaron D Mickle; Robert W Gereau
Journal:  Pain       Date:  2018-09       Impact factor: 6.961

5.  Advances in Gene Delivery Systems.

Authors:  Kenya Kamimura; Takeshi Suda; Guisheng Zhang; Dexi Liu
Journal:  Pharmaceut Med       Date:  2011-10-01

6.  Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats.

Authors:  Tsuyoshi Majima; Yasuhito Funahashi; Shun Takai; William F Goins; Momokazu Gotoh; Pradeep Tyagi; Joseph C Glorioso; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2015-08-31       Impact factor: 5.695

Review 7.  Gene delivery with viral vectors for cerebrovascular diseases.

Authors:  Yu Gan; Zheng Jing; Ruth Anne Stetler; Guodong Cao
Journal:  Front Biosci (Elite Ed)       Date:  2013-01-01

8.  Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz; Howard J Federoff
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-04

Review 9.  Herpes simplex virus-based nerve targeting gene therapy in pain management.

Authors:  James R Goss; David Krisky; James Wechuck; Darren Wolfe
Journal:  J Pain Res       Date:  2014-01-20       Impact factor: 3.133

10.  An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain.

Authors:  Bonnie Reinhart; William F Goins; Asaff Harel; Suchita Chaudhry; James R Goss; Naoki Yoshimura; William C de Groat; Justus B Cohen; Joseph C Glorioso
Journal:  Mol Ther Methods Clin Dev       Date:  2016-06-22       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.